U.S. Markets closed

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
47.71-0.35 (-0.73%)
At close: 4:01PM EDT
People also watch
NVSGSKAZNLLYNVO
Full screen
Previous Close48.06
Open47.87
Bid0.00 x
Ask0.00 x
Day's Range47.33 - 47.88
52 Week Range36.81 - 50.24
Volume941,576
Avg. Volume1,929,665
Market Cap111.61B
Beta0.76
PE Ratio (TTM)11.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.64 (3.41%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacks2 days ago

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

  • Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
    Zacks2 days ago

    Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

    Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

  • Reuters2 days ago

    EU follows U.S. in backing Sanofi, Regeneron eczema drug

    The European Medicines Agency on Friday recommended approval of Regeneron Pharmaceuticals and Sanofi's new drug Dupixent for atopic dermatitis, a product many analysts see as the most important growth driver for the two companies. Recommendations from the agency's expert committee on new drugs are normally endorsed by the European Commission within a couple of months. Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, often unbearable, itching.